# KEYNOTE-603 (NCT03313778)

> Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03313778
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ModernaTX, Inc.
- Conditions: Solid Tumors
- Interventions: mRNA-4157; Pembrolizumab; SoC Treatment
- Enrollment: 161
- Primary outcome: Number of Participants with Adverse Events

## Indexed commentary on KEYNOTE-603 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-603-nct03313778